[{"address1": "Cedar Brook Corporate Center", "address2": "4-B Cedar Brook Drive", "city": "Cranbury", "state": "NJ", "zip": "08512", "country": "United States", "phone": "609 495 2200", "fax": "609 495 2202", "website": "https://palatin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carl  Spana Ph.D.", "age": 62, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1074250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Burns  McClellan", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen A. Slusher Esq.", "title": "Chief Legal Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael B. Raizman M.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James E. Hattersley B.A., M.S.", "age": 64, "title": "Senior Vice President of Business Development", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Dodd Ph.D.", "title": "Senior Vice President of Preclinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Jordan", "title": "Senior Vice President of Program Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.palatin.com/investorcenter/overview.asp", "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.17, "open": 0.103, "dayLow": 0.0866, "dayHigh": 0.107, "regularMarketPreviousClose": 0.17, "regularMarketOpen": 0.103, "regularMarketDayLow": 0.0866, "regularMarketDayHigh": 0.107, "payoutRatio": 0.0, "beta": 0.945, "forwardPE": 0.05005319, "volume": 14571856, "regularMarketVolume": 14571856, "averageVolume": 1767150, "averageVolume10days": 2847903, "averageDailyVolume10Day": 2847903, "bid": 0.094, "ask": 0.0941, "bidSize": 900, "askSize": 1300, "marketCap": 2447145, "fiftyTwoWeekLow": 0.035, "fiftyTwoWeekHigh": 2.13, "priceToSalesTrailing12Months": 6.9918427, "fiftyDayAverage": 0.4095126, "twoHundredDayAverage": 0.92390466, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -611669, "profitMargins": 0.0, "floatShares": 23533730, "sharesOutstanding": 26005800, "sharesShort": 7997487, "sharesShortPriorMonth": 1523889, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.3075, "heldPercentInsiders": 0.02632, "heldPercentInstitutions": 0.14217, "shortRatio": 8.58, "shortPercentOfFloat": 0.31280002, "impliedSharesOutstanding": 26005800, "bookValue": -0.272, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -26952212, "trailingEps": -1.54, "forwardEps": 1.88, "lastSplitFactor": "1:25", "lastSplitDate": 1661904000, "enterpriseToRevenue": -1.748, "enterpriseToEbitda": 0.02, "52WeekChange": -0.93236715, "SandP52WeekChange": 0.12632763, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "PTN", "underlyingSymbol": "PTN", "shortName": "Palatin Technologies, Inc.", "longName": "Palatin Technologies, Inc.", "firstTradeDateEpochUtc": 783613800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef61cf2b-791e-37b7-b04c-9ccb76a1630d", "messageBoardId": "finmb_32651", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.0941, "targetHighPrice": 7.0, "targetLowPrice": 7.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 3416604, "totalCashPerShare": 0.131, "ebitda": -30075104, "totalDebt": 357744, "quickRatio": 0.357, "currentRatio": 0.384, "totalRevenue": 350000, "revenuePerShare": 0.019, "returnOnAssets": -2.12672, "grossProfits": -20654776, "freeCashflow": -15988286, "operatingCashflow": -26942680, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -86.84211, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-07-01"}]